Larimar Therapeutics Appoints John Harlow As President and COO, Effective September 29
Benzinga Newsdesk 1 month ago
NewsManagement
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and
Larimar Therapeutics, Inc. (Larimar) (NASDAQ:LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.